Notice of Results and Investor Presentation
14/09/2021 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210914:nRSN6269La&default-theme=true
RNS Number : 6269L Instem plc 14 September 2021
Instem plc
("Instem")
Notice of Results and Investor Presentation
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, will announce results for the half year ended 30 June 2021 on
Monday 27 September 2021.
Investor Presentation: 4.00pm, Monday 27 September
Management will be providing a presentation and hosting an Investor Q&A
session on the results and future prospects, as well as the recent acquisition
of PDS Pathology Data Systems Ltd on the day of results, at 4.00pm. Investors
can sign up for free and add to attend the presentation via the following
link: https://www.investormeetcompany.com/instem-plc/register-investor
(https://www.investormeetcompany.com/instem-plc/register-investor)
Questions can be submitted pre-event and at any time during the live
presentation via the Investor Meet Company Platform.
Analyst Presentation: 11:30am, Monday 27 September
Management will be hosting a presentation via web conference on the day of the
results at 11.30am. Analysts wishing to join should register their interest by
emailing instem@walbrookpr.com (mailto:instem@walbrookpr.com) or by
telephoning 020 7933 8780.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Nicholas Johnson
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study ManagementRegulatory
Submissions, Clinical Trial Acceleration, and Informatics-based Insight
Generation.
Instem solutions are in use by over 700 customers worldwide, including all the
largest 25 pharmaceutical companies, enabling clients to bring life enhancing
products to market faster. Instem's portfolio of software solutions increases
client productivity by automating study-related processes while offering the
unique ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform at some stage of their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORSFDFWDEFSESU